Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms

Outcomes with “7+3” are often unsatisfactory in acute myeloid leukemia (AML). Trials demonstrating improved outcomes with high-dose cytarabine, addition of cladribine, or escalated anthracycline doses prompted a phase 1/2 study (NCT02044796) of G-CSF, cladribine, high-dose cytarabine, and dose-escal...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Leukemia
Autors principals: Halpern, Anna B., Othus, Megan, Huebner, Emily M., Scott, Bart L., Becker, Pamela S., Percival, Mary-Elizabeth M., Hendrie, Paul C., Gardner, Kelda M., Chen, Tara L., Buckley, Sarah A., Orlowski, Kaysey F., Anwar, Asma, Appelbaum, Frederick R., Erba, Harry P., Estey, Elihu H., Walter, Roland B.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6192860/
https://ncbi.nlm.nih.gov/pubmed/29720734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-018-0135-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars